P648 Impact of high-dose vitamin D3 supplementation in treatment of Crohn’s disease in remission: a randomised double-blind controlled study
N. Narula*, M. Cooray, R. Anglin, Z. Muqtadir, A. Narula, J. Marshall
McMaster University, Gastroenterology, Hamilton, ON, Canada
Vitamin D deficiency has been implicated in the pathogenesis of Crohn’s disease (CD) and vitamin D supplementation may have a role in the management of CD. The aim of this study was to assess the tolerability and efficacy of high-dose vitamin D3 in patients with CD.
This was a randomised, double-blind placebo-controlled trial of high-dose vitamin D3 at 10 000 IU daily (n = 18) compared with low dose at 1 000 IU daily (n = 16) in patients with CD in remission. The primary outcome was improvement in serum 25-hydroxy-vitamin D levels.
High-dose vitamin D3 at 10 000 IU daily significantly improved 25-hydroxy-vitamin D levels from a mean of 73.5 nmol/L (standard deviation [SD] 11.7 nmol/L) to 160.8 nmol/L (SD 43.2 nmol/L) (p = 0.02). In per-protocol analysis, a lower rate of clinical relapse of CD was observed in patients receiving a high dose (0/12 or 0%) compared with those receiving a low dose of 1 000 IU daily (3/8 or 37.5%) (p = 0.049). Significant improvements in depression and a good safety profile was observed in both groups treated with vitamin D3.
Oral supplementation with high dose vitamin D3 at 10 000 IU daily significantly improved serum 25-hydroxy-vitamin-D levels and led to lower rates of clinical relapse. Larger studies using high-dose vitamin D3 for treatment of inflammatory bowel diseases are warranted.